03.15.21

Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Design

Source: Johnson & Johnson Vision

Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada

The Acuvue Oasys Multifocal is built on the Acuvue Oasys 2-week platform and includes the Pupil Optimized Design technology, used in the 1-DAY Acuvue Moist Multifocal, that is designed for crisp, clear, reliable vision at all distances, enabling patients with presbyopia to see distant, intermediate, and near objects.1  

Acuvue Oasys Multifocal combines three technologies: Pupil Optimized Design, Hybrid Back Curve Technology, and a Proprietary Embedded Wetting Agent to create a lens designed for performance and comfort.1

“This Acuvue Oasys Multifocal contact lens brings a long-awaited solution to patients with presbyopia who have been looking for continuous, clear and comfortable vision at all distances,” Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision, said in a company news release.

Available in both daily disposables and reusables, Acuvue offers multifocal lenses that have the same design, parameters, and fit process across modalities, enabling eye care practitioners (ECPs) to offer a more personalized solution for patients.∞ 1 ECPs fitting patients for the Acuvue Oasys Multifocal can also use the free Acuvue Fit Calculator to quickly and easily find the optimal trial lens power for patients.  

Compared to prior JJV multifocal design; technology optimized for both the parameters of refractive error and add power for a multitude of viewing distances and light levels.
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
§www.clinicaltrials.gov is a website maintained by the NIH. The 29 clinical studies evaluated subjective comfort as a primary or secondary endpoint for ACUVUE® OASYS Brand 2-Weekly Family and for ACUVUE® OASYS 1-Day with HydraLuxe Technology. Review conducted as of November 12, 2020.
×Compared to the leading competitor’s design; technology optimized for both parameters of refractive error and add power.
1 JJV Data on File 2020. ACUVUE® PUPIL OPTIMIZED DESIGN TECHNOLOGY: JJVC Contact Lenses, Design Features, and Associated Benefits.
***Dr. Xiao-Yu Song, MD, PhD is an employee of Johnson & Johnson Vision, Inc. with oversight of Research and Development for both the Surgical Vision and Vision Care organizations.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
¥Euromonitor International; Eyewear 2021 Edition; Value sales at RSP, all retails channels, 2019 data.
****Dr. Susan J. Gromacki is a paid consultant of Johnson & Johnson Vision, Inc.
Compared to prior JJV multifocal design; technology optimized for both the parameters of refractive error and add power for a multitude of viewing distances and light levels.
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
2 American Academy of Ophthalmology, “Global prevalence of presbyopia and vision impairment from uncorrected presbyopia,” (2018). https://www.aaojournal.org/article/S0161-6420(17)33797-1/pdf
3 https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/presbyopia?sso=y 
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.

 

Related Content